Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of BMS-986165 in Moderate to Severe Crohn's Disease
2017-001976-48Phase 2Unknown
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing BMS-986165 active treatment with Placebo (2 arms). Primary endpoints: Clinical remission at Week 12 and Endoscopic response at Week 12. Status: unknown.
02
Drugs
deucravacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2017-001976-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001976-48.